SensoLyte® 520 Factor Xa Assay Kit

Catalog No. ABIN1882459

Product Details

Target: Factor Xa (FXa) (Activated Coagulation Factor X (FXa))

Detection Method: Fluorometric

Application: Fluorescence Resonance Energy Transfer Microscopy (FRET)

Brand: SensoLyte®

Characteristics: The SensoLyte® 520 Factor Xa Assay Kit provides a convenient assay for high throughput screening of FXa inhibitors or continuous assay of enzyme activity. It detects FXa activity using a 5-FAM/QXL™ 520 fluorescence resonance energy transfer (FRET) peptide. In the intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL™ 520. Upon cleavage into two separate fragments by FXa, the fluorescence of 5-FAM is recovered, and can be monitored at excitation/emission wavelengths = 490 nm/520 nm. With excellent fluorescence quantum yield and longer wavelength, 5-FAM shows less interference from autofluorescence of test compounds and cellular components. The assays are performed in a convenient 96-well microplate format.

Application Details

Comment:

FRET-based Assay Kit

Restrictions: For Research Use only

Handling

Handling Advice: Protect Components A and B from light and moisture.

Storage: -80 °C

Storage Comment: Store all kit components at -20 °C, except for Component C. Store Component C at -80 °C. Component D can be stored at room temperature for convenience

Target Details

Target: Factor Xa (FXa) (Activated Coagulation Factor X (FXa))

Alternative Name: Factor Xa (FXa Products)

Synonyms: FX Kit, FXA Kit, coagulation factor X Kit, F10 Kit

Background: Factor Xa (FXa) is a serine endopeptidase composed of two disulfide-linked subunits. FXa leads to blood clot formation by converting prothrombin to thrombin through the prothrombinase complex. FXa is generated from zymogen Factor X via the intrinsic and extrinsic pathways and is the rate-limiting step in the propagation of thrombin generation. In the presence of Ca2+ ions, FXa forms prothrombinase with factor Va on the phospholipid membrane of the activated platelets. FXa has emerged as an attractive target for drug discovery for thromboembolic diseases.